GSDMD KNOCKOUT ALLEVIATES SEPSIS-ASSOCIATED SKELETAL MUSCLE ATROPHY BY INHIBITING IL18/AMPK SIGNALING

Yongsheng Zhang, Tonghan Li, Yukun Liu1

  • 1Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Shock (Augusta, Ga.)
|September 3, 2024
PubMed

Insights

The pyroptosis effector protein GSDMD significantly contributes to sepsis-induced skeletal muscle atrophy. Blocking GSDMD protects against muscle wasting by inhibiting the IL18/AMPK pathway, offering potential therapeutic strategies.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Physiology

Background:

  • Sepsis frequently causes skeletal muscle atrophy, leading to weakness and poor prognosis.
  • Programmed cell death pathways, particularly pyroptosis, are implicated in sepsis-induced muscle loss.
  • The specific role of pyroptosis effector GSDMD in skeletal muscle atrophy remains unclear.

Purpose of the Study:

  • To investigate the role and mechanism of the pyroptosis effector GSDMD in sepsis-induced skeletal muscle atrophy.
  • To evaluate the impact of GSDMD deficiency on muscle wasting in cellular and mouse models of sepsis.

Main Methods:

  • Assessed GSDMD and N-GSDMD levels in septic mouse skeletal muscle.
  • Utilized GSDMD knockout and wild-type mice subjected to cecal ligation and puncture to model sepsis.
  • Examined muscle atrophy, architecture, protein expression, and signaling pathways in vivo and in vitro using siRNA in C2C12 cells.

Main Results:

  • GSDMD expression, specifically N-GSDMD, was elevated in septic mouse skeletal muscle.
  • GSDMD knockout mice showed improved survival, muscle strength, and reduced muscle wasting compared to wild-type septic mice.
  • GSDMD deficiency attenuated sepsis-induced muscle loss by inhibiting the IL18/AMPK signaling pathway.

Conclusions:

  • GSDMD plays a critical role in sepsis-related skeletal muscle atrophy.
  • Lack of GSDMD confers protection against muscle wasting by modulating the IL18/AMPK pathway.
  • Targeting GSDMD may offer a therapeutic approach for preventing or treating sepsis-induced muscle atrophy.